Jacob van Naarden - 10 Feb 2025 Form 4 Insider Report for ELI LILLY & Co (LLY)

Role
EVP & Pres., Lilly Oncology
Signature
/s/ Jonathan Groff for Jacob Van Naarden, pursuant to authorization on file
Issuer symbol
LLY
Transactions as of
10 Feb 2025
Net transactions value
+$5,303,491
Form type
4
Filing time
12 Feb 2025, 16:28:10 UTC
Previous filing
04 Feb 2025
Next filing
13 Aug 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LLY Common Stock Award $5,303,491 +6,104 +45% $868.88 19,562 10 Feb 2025 Direct
holding LLY Common Stock 4,302 10 Feb 2025 By spouse F1
holding LLY Common Stock 4,342 10 Feb 2025 Van Naarden Family Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LLY Restricted Stock Unit Award $0 +4,108 $0.000000 4,108 10 Feb 2025 Common Stock 4,108 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2 Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.